Physician profile
Crystal Carter
NPI 1093109704
$2,648.81
in general payments reported to CMS, 2019-2025
22 companies · $785 in 2025
The $785 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $119 · 2023: $974 · 2024: $771 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,530.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $467.90 | 2023-2024 | Spravato |
| Lilly USA, LLC | $334.21 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $330.72 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $298.75 | 2023-2025 | Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $187.87 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbott Laboratories | $182.09 | 2022-2025 | Freestyle Libre |
| Pfizer INC. | $156.12 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.09 | 2023-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $91.84 | 2023 | Amvuttra |
| Amgen INC. | $80.84 | 2024-2025 | Evenity, Prolia, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $75.88 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Corcept Therapeutics | $46.05 | 2025 | Korlym |
| Exact Sciences Corporation | $44.43 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $40.84 | 2023-2024 | |
| Dexcom, INC. | $35.10 | 2024 | Dexcom G6 Transmitter |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medline Industries LP | $28.91 | 2023 | |
| Astellas Pharma US INC | $24.39 | 2025 | Xtandi |
| Shield Therapeutics INC | $23.61 | 2025 | |
| Taiho Oncology, INC. | $21.44 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.35 | 2023 | |
| Edwards Lifesciences Corporation | $16.34 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Idorsia Pharmaceuticals US INC | $15.04 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.